Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Capsules
Reexamination Certificate
2007-09-18
2007-09-18
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Capsules
C424S451000, C424S464000, C424S468000, C424S474000, C424S475000, C424S479000, C424S480000, C424S482000, C424S490000, C424S493000, C424S494000, C424S497000
Reexamination Certificate
active
10392586
ABSTRACT:
Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates including the opioid analgesic in sustained release form. The substrates have a diameter from about 0.1 mm to about 3 mm.
REFERENCES:
patent: 3634584 (1972-01-01), Poole
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3870790 (1975-03-01), Lowey et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4377568 (1983-03-01), Chopra
patent: 4385078 (1983-05-01), Onda et al.
patent: 4389393 (1983-06-01), Schor et al.
patent: 4483847 (1984-11-01), Augart
patent: 4520172 (1985-05-01), Lehmann et al.
patent: 4548990 (1985-10-01), Mueller et al.
patent: 4557925 (1985-12-01), Lindahl et al.
patent: 4600645 (1986-07-01), Ghebre-Sellassie et al.
patent: 4708874 (1987-11-01), De Haan et al.
patent: 4728513 (1988-03-01), Ventouras
patent: 4797410 (1989-01-01), El-Fakahany
patent: 4806337 (1989-02-01), Snipes et al.
patent: 4828836 (1989-05-01), Elger et al.
patent: 4834984 (1989-05-01), Goldie et al.
patent: 4834985 (1989-05-01), Elger et al.
patent: 4844907 (1989-07-01), Elger et al.
patent: 4844909 (1989-07-01), Goldie et al.
patent: 4861598 (1989-08-01), Oshlack
patent: 4970075 (1990-11-01), Oshlack
patent: 4983730 (1991-01-01), Domeshek et al.
patent: 4990341 (1991-02-01), Goldie et al.
patent: 5007790 (1991-04-01), Shell
patent: 5024842 (1991-06-01), Edgren et al.
patent: 5071646 (1991-12-01), Malkowska et al.
patent: 5122384 (1992-06-01), Paradissis et al.
patent: 5133974 (1992-07-01), Paradissis et al.
patent: 5169645 (1992-12-01), Shukla et al.
patent: 5178868 (1993-01-01), Malmqvist et al.
patent: 5202128 (1993-04-01), Morella et al.
patent: 5266331 (1993-11-01), Oshlack et al.
patent: 5273760 (1993-12-01), Oshlack et al.
patent: 5283065 (1994-02-01), Doyon et al.
patent: 5286493 (1994-02-01), Oshlack et al.
patent: 5321012 (1994-06-01), Mayer et al.
patent: 5330766 (1994-07-01), Morella et al.
patent: 5378474 (1995-01-01), Morella et al.
patent: 5411745 (1995-05-01), Oshlack et al.
patent: 5445829 (1995-08-01), Paradissis et al.
patent: 5456923 (1995-10-01), Nakamichi et al.
patent: 5460826 (1995-10-01), Merrill et al.
patent: 5472712 (1995-12-01), Oshlack et al.
patent: 5500227 (1996-03-01), Oshlack et al.
patent: 5508042 (1996-04-01), Oshlack et al.
patent: 5520931 (1996-05-01), Persson et al.
patent: 5549912 (1996-08-01), Oshlack et al.
patent: 5580578 (1996-12-01), Oshlack et al.
patent: 5601842 (1997-02-01), Bartholomaeus
patent: 5614218 (1997-03-01), Olsson et al.
patent: 5672360 (1997-09-01), Sackler et al.
patent: 6103261 (2000-08-01), Chasin et al.
patent: 6143322 (2000-11-01), Sackler et al.
patent: 6572885 (2003-06-01), Oshlack et al.
patent: 9047732 (1990-07-01), None
patent: 9341654 (1995-02-01), None
patent: 2082573 (1992-11-01), None
patent: 2131350 (1994-09-01), None
patent: 0097523 (1984-01-01), None
patent: 0108218 (1984-05-01), None
patent: 0147780 (1985-07-01), None
patent: 0235986 (1987-09-01), None
patent: 0253104 (1988-01-01), None
patent: 0271193 (1988-06-01), None
patent: 0377518 (1990-07-01), None
patent: 377518 (1990-07-01), None
patent: 0388954 (1990-09-01), None
patent: 0415693 (1991-03-01), None
patent: 0553392 (1992-08-01), None
patent: 0532348 (1993-03-01), None
patent: 0533297 (1993-03-01), None
patent: 0534628 (1993-03-01), None
patent: 0535841 (1993-04-01), None
patent: 0546676 (1993-06-01), None
patent: 0548448 (1993-06-01), None
patent: 0580860 (1994-02-01), None
patent: 0630646 (1994-06-01), None
patent: 0631781 (1994-06-01), None
patent: 0636370 (1994-06-01), None
patent: 0636366 (1994-07-01), None
patent: 0609961 (1994-08-01), None
patent: 0665010 (1995-08-01), None
patent: 377518 (1996-02-01), None
patent: 2053681 (1981-02-01), None
patent: 2178313 (1987-02-01), None
patent: 6330427 (1988-02-01), None
patent: 03114 (1991-01-01), None
patent: 4312524 (1992-11-01), None
patent: 4321621 (1992-11-01), None
patent: 177293 (1992-01-01), None
patent: 9201446 (1992-02-01), None
patent: 9206679 (1992-04-01), None
patent: 9304675 (1993-03-01), None
patent: 9310765 (1993-06-01), None
patent: 9318753 (1993-09-01), None
patent: 9403160 (1994-02-01), None
patent: 9403161 (1994-02-01), None
patent: 9405262 (1994-03-01), None
patent: 9422431 (1994-10-01), None
patent: 9600066 (1996-01-01), None
patent: 9601629 (1996-01-01), None
patent: 9614058 (1996-03-01), None
Advertisement Roxanol SR, ©1998 Roxane Laboratories, Inc.
R. Kaiko and T. Hunt, “Comparison of the Pharmacokinetic Profiles of Two New Oral Controlled-Release Morphine Formulations in Healthy Young Adults”, Clin, Thera., vol. 13 No. 4, 1991.
R. Wet and C. Maccarrone, “Single Dose Pharmacokinetics of a New Oral Sustained-Release Morphine Formulation, Kapanol® Capsules”, Abstracts-7th World Congress on Pain, Aug. 26, 1993, Abstracts 997-1001.
S. Bloomfield, et al., “Analgesic efficacy and potency of two oral controlled-release morphine preparations”, Clin. Pharmacol. Ther., vol. 53, No. 4, pp. 469-478, ©1993.
Advertisement: MS Contin®, ©1986, 1987, The Purdue Frederick Company.
Abraham Sunshine, et al., “Analgesic oral efficacy of tramadol hydrochloride in postoperative pain”,Clin. Pharmacol. Ther., Jun. 1992, pp. 740-746.
E. Beubler, “Medikamentose Schmerztherapie: Kriterien, Moglichkeiten, Risken”,Therapiewoche Osterreich, 7,2 (1992), pp. 90-96, with English translation.
Geoffrey K. Gourlay, Ph.D., et al., Influence of a high-fat meal on the absorption of morphine from oral solutions:,Clin. Pharmacol. Ther., Oct. 1989, pp. 463-468.
Robert Kaiko, et al., “A Single-Dose Study Of The Effect Of Food Ingestion And Timing Of Dose Administration On The Pharmacokinetic Profile Of 30-MG Sustained-Release Morphine Sulfate Tablets”, Current Therapeutic Research, vol. 47, No. 5, May 1990, pp. 869-878.
Geoffrey K. Gourlay, Ph.D., “The Reproducibility of Bioavailability of Oral Morphine form Solution Under Fed and Fasted Conditions”. Journal of Pain and Symptoms Management, vol. 6, No. 7, Oct. 1991, pp. 431-436.
Robert F. Kaiko, et al. “Controlled-Release Morphine Bioavailability (MS Contin Tablets) in the Presence and Absence of Food”, The Hospice Journal, vol. 6(4) 1990, pp. 17-30.
N. Yokokawa, et al., “Relationship between plasma concentration of morphine and analgesic effectiveness”,Postgrad Med J, (1991) 67 (Suppl. 2) pp. 550-554.
Physician Desk Reference 1994, 48thEdition, pp. 1821-1824.
Abstracts from the Twelfth Annual Congress of the Oncology Nursing Society, May 1987.
J. Lapin et al., “Cancer Pain Management with a Controlled Release Oral Morphine Preparation”, Journ. of Pain and Symptom Manag., v 4 (3), pp. 146-151, 1989.
J. Lapin et al., Guidelines for use of Controlled Release Oral Morphine in Cancer Pain Management, Cancer Nursing, v 12 (4), pp. 202-208, 1989.
R.F. Kaiko, “The Pre-and Postoperative Use of Controlled-Release Morphine (MS Contin Tablets): A Review of the Published Literature”, Medical Department, The Purdue Frederick Company, Royal Society of Medical Services, International Congress, Symposium Services, No. 149, pp. 147-160 (1989).
H.F. Slowey et al., “Effect of Premedication with Controlled-Release Oral Morphine on Postoperative Pain”, Anaesthesia, 1985, vol. 40, pp. 438-440.
MS Contin—Frequency of Daily Dosing, Jan.-Nov. 1990.
MS Contin—Frequency of Daily Dosing (NDTI)—Jun. 1991-May 1992.
R.K. Portenoy, et al., “A Radomized, Double-Blind, Double-Dummy, Crossover Study Comparing the Pharmacokinetics and Pharmacodynamics of Kapanol® Capsules Given Every 24 hours and Every 12 hours with MS Contin® Tablets Given Every 12 Hours in the Management of Patients with Moderate to Severe Chronic Pain” no date.
Maccarrone C. et al; Single dose Pharmacokinetics o
Chasin Mark
Oshlack Benjamin
Jones Day
Page Thurman K.
Purdue Pharma L.P.
Sheikh Humera N.
LandOfFree
Orally administrable opioid formulations having extended... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Orally administrable opioid formulations having extended..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Orally administrable opioid formulations having extended... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3773631